At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
TAK-906 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Randomized, Two-Way Crossover Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of OATP1B1 and OATP1B3 on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-906 and Rifampin for Healthy Volunteers. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of single dose intravenous rifampin on the single-dose PK of orally administered TAK-906.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartOct 2019
Primary CompletionNov 2019
Study CompletionNov 2019
TodayJul 2026
First PostedOct 9, 2019
Enrollment StartOct 15, 2019
Primary CompletionNov 4, 2019
Study CompletionNov 16, 2019
TodayJul 2, 2026
Enrollment to primary: 19 daysPosted 6.7 years ago
Interventions
TAK-906drug
TAK-906 capsule.
Rifampindrug
Rifampin infusion.